Public Market Listing
HLUN.BNasdaq Copenhagen
Live quotes, historical charts, and market capitalization for H. Lundbeck are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(10 total)
10Total Assets
7Approved
2Phase 3 / Filed
1Phase 1–2 / Early
6Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Approved | Dopamine D2 and serotonin 5-HT1A receptors (partial agonist) · Dopamine D2/D3 and serotonin 5-HT1A receptor · Dopamine D2 receptor (partial agonist)Small molecule | Schizophrenia | |
| Approved | Dopamine D2/D3 and serotonin 5-HT1A receptorSmall molecule | Schizophrenia | |
| Approved | Dopamine D2/D3 and serotonin 5-HT1A receptorSmall molecule | Alzheimer's DiseaseMajor Depressive DisorderSchizophrenia | |
| Approved | GABA-A receptorSmall molecule | Epilepsy | |
| Approved | —Monoclonal antibody | Migraine | |
| Approved | GABA transaminase (GABA-T)Small molecule | Epilepsy | |
Vortioxetine(Trintellix) | Approved | Serotonin transporter + multiple 5-HT receptorsSmall molecule | Major Depressive Disorder |
| Phase 3 | Serotonin 5-HT2C receptor (agonist)Small molecule | Epilepsy | |
| Phase 3 | norepinephrine precursorSmall molecule | Parkinson's Disease | |
| Phase 2 | D1/D2Small molecule | Parkinson's Disease |
Upcoming events
Research
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.